Modern methods for delivery of drugs across the blood–brain barrier

Neuwelt, 2008, Strategies to advance translational research into brain barriers, Lancet Neurol., 7, 84, 10.1016/S1474-4422(07)70326-5 Pardridge, 2003, Blood–brain barrier drug targeting: the future of brain drug development, Mol. Interv., 3, 90, 10.1124/mi.3.2.90 Rip, 2009, Differential receptor-mediated drug targeting to the diseased brain, Expert Opin. Drug Deliv., 6, 227, 10.1517/17425240902806383 Pathan, 2009, CNS drug delivery systems: novel approaches, Recent Pat. Drug Deliv. Formul., 3, 71, 10.2174/187221109787158355 Hawkins, 2008, Pathophysiology of the blood–brain barrier: animal models and methods, Curr. Top. Dev. Biol., 80, 277, 10.1016/S0070-2153(07)80007-X Stewart, 2000, Endothelial vesicles in the blood–brain barrier: are they related to permeability?, Cell. Mol. Neurobiol., 20, 149, 10.1023/A:1007026504843 Abbott, 2005, Dynamics of CNS barriers: evolution, differentiation, and modulation, Cell. Mol. Neurobiol., 25, 5, 10.1007/s10571-004-1374-y Oldendorf, 1977, The large apparent work capability of the blood–brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat, Ann. Neurol., 1, 409, 10.1002/ana.410010502 Hawkins, 2005, The blood–brain barrier/neurovascular unit in health and disease, Pharmacol. Rev., 57, 173, 10.1124/pr.57.2.4 Persidsky, 2006, Blood–brain barrier: structural components and function under physiologic and pathologic conditions, J. Neuroimmune Pharmacol., 1, 223, 10.1007/s11481-006-9025-3 Abbott, 2006, Astrocyte-endothelial interactions at the blood–brain barrier, Nat. Rev. Neurosci., 7, 41, 10.1038/nrn1824 Ramsauer, 1998, Regulation of a blood–brain barrier-specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) under cell culture conditions, J. Cereb. Blood Flow Metab., 18, 1270, 10.1097/00004647-199811000-00014 Ramsauer, 2002, Angiogenesis of the blood–brain barrier in vitro and the function of cerebral pericytes, FASEB J., 16, 1274, 10.1096/fj.01-0814fje Dohgu, 2005, Brain pericytes contribute to the induction and up-regulation of blood–brain barrier functions through transforming growth factor-beta production, Brain Res., 1038, 208, 10.1016/j.brainres.2005.01.027 Wekerle, 2002, Immune protection of the brain-efficient and delicate, J. Infect. Dis., 186, S140, 10.1086/344937 Daneman, 2009, The gut immune barrier and the blood–brain barrier: are they so different?, Immunity, 31, 722, 10.1016/j.immuni.2009.09.012 Williams, 2001, Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system, Glia, 36, 156, 10.1002/glia.1105 Streit, 2005, Role of microglia in the central nervous system's immune response, Neurol. Res., 27, 685, 10.1179/016164105X49463a Pardridge, 2005, Molecular biology of the blood–brain barrier, Mol. Biotechnol., 30, 57, 10.1385/MB:30:1:057 Abbott, 1996, Transporting therapeutics across the blood–brain barrier, Mol. Med. Today, 2, 106, 10.1016/1357-4310(96)88720-X Lee, 2001, Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations, Pharmacol. Rev., 53, 569, 10.1146/annurev.pharmtox.41.1.569 Kemper, 2004, Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?, Cancer Treat. Rev., 30, 415, 10.1016/j.ctrv.2004.04.001 Pardridge, 2005, Drug and gene targeting to the brain via blood–brain barrier receptor-mediated transport systems, Int. Congr. Ser., 1277, 49, 10.1016/j.ics.2005.02.011 Herve, 2008, CNS delivery via adsorptive transcytosis, AAPS J., 10, 455, 10.1208/s12248-008-9055-2 Jain, 2003, RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting, Int. J. Pharm., 261, 43, 10.1016/S0378-5173(03)00269-2 Chretien, 2002, Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia, J. Infect. Dis., 186, 522, 10.1086/341564 Gonzalez-Scarano, 2005, The neuropathogenesis of AIDS, Nat. Rev. Immunol., 5, 69, 10.1038/nri1527 Park, 2008, Trojan monocytes for improved drug delivery to the brain, J. Control. Release, 132, 75, 10.1016/j.jconrel.2008.10.009 Chen, 2004, Drug delivery across the blood–brain barrier, Curr. Drug Deliv., 1, 361, 10.2174/1567201043334542 de Boer, 2007, Drug targeting to the brain, Annu. Rev. Pharmacol. Toxicol., 47, 323, 10.1146/annurev.pharmtox.47.120505.105237 Cardoso, 2010, Looking at the blood–brain barrier: molecular anatomy and possible investigation approaches, Brain Res. Rev., 64, 328, 10.1016/j.brainresrev.2010.05.003 Wolburg, 2002, Tight junctions of the blood–brain barrier: development, composition and regulation, Vascul. Pharmacol., 38, 323, 10.1016/S1537-1891(02)00200-8 Bernacki, 2008, Physiology and pharmacological role of the blood–brain barrier, Pharmacol. Rep., 60, 600 Huber, 2001, Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier, Trends Neurosci., 24, 719, 10.1016/S0166-2236(00)02004-X Petty, 2002, Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation, Prog. Neurobiol., 68, 311, 10.1016/S0301-0082(02)00128-4 Yu, 2005, Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells, Am. J. Physiol. Cell Physiol., 288, C1231, 10.1152/ajpcell.00581.2004 Nitta, 2003, Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice, J. Cell Biol., 161, 653, 10.1083/jcb.200302070 Fontijn, 2006, Limited contribution of claudin-5-dependent tight junction strands to endothelial barrier function, Eur. J. Cell Biol., 85, 1131, 10.1016/j.ejcb.2006.07.005 Soma, 2004, Thr(207) of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP, Exp. Cell Res., 300, 202, 10.1016/j.yexcr.2004.07.012 Matter, 2003, Holey barrier: claudins and the regulation of brain endothelial permeability, J. Cell Biol., 161, 459, 10.1083/jcb.200304039 Zlokovic, 2008, The blood–brain barrier in health and chronic neurodegenerative disorders, Neuron, 57, 178, 10.1016/j.neuron.2008.01.003 Vorbrodt, 2004, Molecular anatomy of interendothelial junctions in human blood–brain barrier microvessels, Folia Histochem. Cytobiol., 42, 67 Bennett, 2010, Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE, J. Neuroimmunol., 229, 180, 10.1016/j.jneuroim.2010.08.011 Cook, 2008, TGF-beta1 induces rearrangement of FLK-1-VE-cadherin-beta-catenin complex at the adherens junction through VEGF-mediated signaling, J. Cell. Biochem., 105, 1367, 10.1002/jcb.21935 Lim, 2008, Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells, J. Neurochem., 106, 1855 Vorbrodt, 2008, Increased expression of beta-catenin in brain microvessels of a segmentally trisomic (Ts65Dn) mouse model of Down syndrome, Brain Cell Biol., 36, 203, 10.1007/s11068-008-9038-3 Deli, 2009, Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery, Biochim. Biophys. Acta, 1788, 892, 10.1016/j.bbamem.2008.09.016 Stamatovic, 2008, Brain endothelial cell–cell junctions: how to “open” the blood brain barrier, Curr. Neuropharmacol., 6, 179, 10.2174/157015908785777210 Harhaj, 2006, VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability, Invest. Ophthalmol. Vis. Sci., 47, 5106, 10.1167/iovs.06-0322 Clarke, 2000, Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets, J. Cell Sci., 113, 3187, 10.1242/jcs.113.18.3187 Potter, 2005, Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state, J. Biol. Chem., 280, 31906, 10.1074/jbc.M505568200 Haorah, 2007, Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood–brain barrier dysfunction, J. Neurochem., 101, 566, 10.1111/j.1471-4159.2006.04393.x Lohmann, 2004, Tyrosine phosphatase inhibition induces loss of blood–brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways, Brain Res., 995, 184, 10.1016/j.brainres.2003.10.002 Kumar, 2009, Molecular mechanisms of endothelial hyperpermeability: implications in inflammation, Expert Rev. Mol. Med., 11, e19, 10.1017/S1462399409001112 Gonzalez-Mariscal, 2008, Crosstalk of tight junction components with signaling pathways, Biochim. Biophys. Acta, 1778, 729, 10.1016/j.bbamem.2007.08.018 Hirase, 2001, Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms, J. Biol. Chem., 276, 10423, 10.1074/jbc.M007136200 Deli, 2005, Permeability studies on in vitro blood–brain barrier models: physiology, pathology, and pharmacology, Cell. Mol. Neurobiol., 25, 59, 10.1007/s10571-004-1377-8 Yuan, 2002, Protein kinase signaling in the modulation of microvascular permeability, Vascul. Pharmacol., 39, 213, 10.1016/S1537-1891(03)00010-7 Watson, 1991, The tight-junction-specific protein ZO-1 is a component of the human and rat blood–brain barriers, Neurosci. Lett., 129, 6, 10.1016/0304-3940(91)90708-2 Tu, 2011, Baicalin inhibits TLR2/4 signaling pathway in rat brain following permanent cerebral ischemia, Inflammation, 34, 463, 10.1007/s10753-010-9254-8 Huber, 2001, Inflammatory pain alters blood–brain barrier permeability and tight junctional protein expression, Am. J. Physiol. Heart Circ. Physiol., 280, H1241, 10.1152/ajpheart.2001.280.3.H1241 Willis, 2004, Reversible disruption of tight junction complexes in the rat blood–brain barrier, following transitory focal astrocyte loss, Glia, 48, 1, 10.1002/glia.20049 Holman, 2011, The blood–brain barrier, chemokines and multiple sclerosis, Biochim. Biophys. Acta, 1812, 220, 10.1016/j.bbadis.2010.07.019 Tsao, 2001, Tumour necrosis factor-alpha causes an increase in blood–brain barrier permeability during sepsis, J. Med. Microbiol., 50, 812, 10.1099/0022-1317-50-9-812 Bowman, 2007, Blood–brain barrier impairment in Alzheimer disease: stability and functional significance, Neurology, 68, 1809, 10.1212/01.wnl.0000262031.18018.1a Desai, 2007, Blood–brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy, Cell Transplant., 16, 285, 10.3727/000000007783464731 Marchi, 2007, Seizure-promoting effect of blood–brain barrier disruption, Epilepsia, 48, 732, 10.1111/j.1528-1167.2007.00988.x Sato, 1994, Effect of barrier opening on brain edema in human brain tumors, Acta. Neurochir. Suppl. (Wien), 60, 116 Fang, 2010, Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia–reperfusion injury, Eur. J. Pharm. Sci., 39, 8, 10.1016/j.ejps.2009.10.002 Cheng, 2010, Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood–brain barrier disruption, Drug Metab. Dispos., 38, 1355, 10.1124/dmd.110.033324 Lee, 2004, Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders, Pharm. Res., 21, 1313, 10.1023/B:PHAM.0000036905.82914.8e Cirrito, 2005, P-glycoprotein deficiency at the blood–brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model, J. Clin. Invest., 115, 3285, 10.1172/JCI25247 Kortekaas, 2005, Blood–brain barrier dysfunction in parkinsonian midbrain in vivo, Ann. Neurol., 57, 176, 10.1002/ana.20369 Marroni, 2003, Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy, Curr. Drug Targets, 4, 297, 10.2174/1389450033491109 Spudich, 2006, Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia, Nat. Neurosci., 9, 487, 10.1038/nn1676 Batrakova, 2008, Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers, J. Control. Release, 130, 98, 10.1016/j.jconrel.2008.04.013 Begley, 2004, ABC transporters and the blood–brain barrier, Curr. Pharm. Des., 10, 1295, 10.2174/1381612043384844 Schinkel, 2003, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, Adv. Drug Deliv. Rev., 55, 3, 10.1016/S0169-409X(02)00169-2 Löscher, 2005, Blood–brain barrier active efflux transporters: ATP-binding cassette gene family, NeuroRx, 2, 86, 10.1602/neurorx.2.1.86 Duchini, 1996, Effects of tumor necrosis factor-alpha and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells, J. Investig. Med., 44, 474 Lu, 2001, Cellular inflammatory response associated with breakdown of the blood–brain barrier after closed head injury in rats, J. Neurotrauma, 18, 399, 10.1089/089771501750170976 Fillebeen, 1999, Tumor necrosis factor-alpha increases lactoferrin transcytosis through the blood–brain barrier, J. Neurochem., 73, 2491, 10.1046/j.1471-4159.1999.0732491.x Cipolla, 2004, Transcellular transport as a mechanism of blood–brain barrier disruption during stroke, Front. Biosci., 9, 777, 10.2741/1282 Pardridge, 1997, Drug delivery to the brain, J. Cereb. Blood Flow Metab., 17, 713, 10.1097/00004647-199707000-00001 Pardridge, 1987, Human blood–brain barrier transferrin receptor, Metabolism, 36, 892, 10.1016/0026-0495(87)90099-0 Moos, 2004, The metabolism of neuronal iron and its pathogenic role in neurological disease: review, Ann. N. Y. Acad. Sci., 1012, 14, 10.1196/annals.1306.002 Morris, 1994, Transferrin receptors in the normal human hippocampus and in Alzheimer's disease, Neuropathol. Appl. Neurobiol., 20, 473, 10.1111/j.1365-2990.1994.tb00998.x Kalaria, 1992, Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease, Brain Res., 585, 87, 10.1016/0006-8993(92)91193-I Wu, 2003, Iron and iron-handling proteins in the brain after intracerebral hemorrhage, Stroke, 34, 2964, 10.1161/01.STR.0000103140.52838.45 Recht, 1990, Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy, J. Neurosurg., 72, 941, 10.3171/jns.1990.72.6.0941 Frolich, 1998, Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease, J. Neural Transm., 105, 423, 10.1007/s007020050068 Xie, 2002, Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor, J. Neurosci., 22, RC221, 10.1523/JNEUROSCI.22-10-j0001.2002 Dehouck, 1997, A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier, J. Cell Biol., 138, 877, 10.1083/jcb.138.4.877 Herz, 2001, LRP: a multifunctional scavenger and signaling receptor, J. Clin. Invest., 108, 779, 10.1172/JCI200113992 Shibata, 2000, Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier, J. Clin. Invest., 106, 1489, 10.1172/JCI10498 Deane, 2005, IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood–brain barrier neonatal Fc receptor, J. Neurosci., 25, 11495, 10.1523/JNEUROSCI.3697-05.2005 Ueno, 2010, The expression of LDL receptor in vessels with blood–brain barrier impairment in a stroke-prone hypertensive model, Histochem. Cell Biol., 133, 669, 10.1007/s00418-010-0705-y Mishima, 1996, Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrain, Neurosci. Lett., 213, 153, 10.1016/S0304-3940(96)12850-0 Gaillard, 2005, Diphtheria toxin receptor-targeted brain drug delivery, Int. Congr. Ser., 1277, 185, 10.1016/j.ics.2005.02.022 Opanashuk, 1999, Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action, J. Neurosci., 19, 133, 10.1523/JNEUROSCI.19-01-00133.1999 Kawahara, 1999, The gene for heparin-binding epidermal growth factor-like growth factor is stress-inducible: its role in cerebral ischemia, J. Cereb. Blood Flow Metab., 19, 307, 10.1097/00004647-199903000-00009 Jin, 2004, Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat, J. Cereb. Blood Flow Metab., 24, 399, 10.1097/00004647-200404000-00005 Yu, 2011, Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target, Sci. Transl. Med., 3, 84ra44, 10.1126/scitranslmed.3002230 Vass, 1993, Bone marrow-derived elements in the peripheral nervous system. An immunohistochemical and Ultrastructural investigation in Chimeric rats, Lab. Invest., 69, 275 Charlier, 2009, Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans, Infect. Immun., 77, 120, 10.1128/IAI.01065-08 Strazza, 2011, Breaking down the barrier: the effects of HIV-1 on the blood–brain barrier, Brain Res., 1399, 96, 10.1016/j.brainres.2011.05.015 Huang, 2006, Inflammation in stroke and focal cerebral ischemia, Surg. Neurol., 66, 232, 10.1016/j.surneu.2005.12.028 Jimenez, 2005, Mult. Scler., 11, 310, 10.1191/1352458505ms1184oa Floris, 2002, Interferon-beta directly influences monocyte infiltration into the central nervous system, J. Neuroimmunol., 127, 69, 10.1016/S0165-5728(02)00098-X Roggendorf, 1996, Distribution and characterization of microglia/macrophages in human brain tumors, Acta Neuropathol., 92, 288, 10.1007/s004010050520 Streit, 1994, Cellular immune response in brain tumors, Neuropathol. Appl. Neurobiol., 20, 205 Morantz, 1979, Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors, J. Neurosurg., 50, 305, 10.3171/jns.1979.50.3.0305 Morantz, 1979, Macrophages in experimental and human brain tumors. Part 1: studies of the macrophage content of experimental rat brain tumors of varying immunogenicity, J. Neurosurg., 50, 298, 10.3171/jns.1979.50.3.0298 Bajetto, 2006, Expression of CXC chemokine receptors 1–5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration, Neurochem. Int., 49, 423, 10.1016/j.neuint.2006.03.003 Desbaillets, 1994, Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro, Int. J. Cancer, 58, 240, 10.1002/ijc.2910580216 Djukic, 2006, Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice, Brain, 129, 2394, 10.1093/brain/awl206 Afergan, 2008, Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes, J. Control. Release, 132, 84, 10.1016/j.jconrel.2008.08.017 Hynynen, 2008, Ultrasound for drug and gene delivery to the brain, Adv. Drug Deliv. Rev., 60, 1209, 10.1016/j.addr.2008.03.010 Stam, 2010, Electromagnetic fields and the blood–brain barrier, Brain Res. Rev., 65, 80, 10.1016/j.brainresrev.2010.06.001 Karyekar, 2003, Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells, J. Pharm. Sci., 92, 414, 10.1002/jps.10310 Abbott, 2000, Inflammatory mediators and modulation of blood–brain barrier permeability, Cell. Mol. Neurobiol., 20, 131, 10.1023/A:1007074420772 Vajkoczy, 2004, Vascular microenvironment in gliomas, Cancer Treat. Res., 117, 249, 10.1007/978-1-4419-8871-3_15 Inamura, 1994, Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma, Neurol. Res., 16, 125, 10.1080/01616412.1994.11740209 Nomura, 1994, Effect of histamine on the blood-tumor barrier in transplanted rat brain tumors, Acta. Neurochir. Suppl. (Wien), 60, 400 Sarker, 2002, The role of guanylyl cyclases in the permeability response to inflammatory mediators in pial venular capillaries in the rat, J. Physiol., 540, 209, 10.1113/jphysiol.2001.012912 Yamauchi, 2007, An inhibitory role of nitric oxide in the dynamic regulation of the blood–brain barrier function, Cell. Mol. Neurobiol., 27, 263, 10.1007/s10571-007-9139-z Emerich, 1998, Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7), Brain Res., 801, 259, 10.1016/S0006-8993(98)00571-X Emerich, 1999, Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters, Br. J. Cancer, 80, 964, 10.1038/sj.bjc.6690450 Emerich, 2000, Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain, Pharm. Res., 17, 1212, 10.1023/A:1026462629438 Borlongan, 2003, Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull., 60, 297, 10.1016/S0361-9230(03)00043-1 Sanovich, 1995, Pathway across blood–brain barrier opened by the bradykinin agonist, RMP-7, Brain Res., 705, 125, 10.1016/0006-8993(95)01143-9 Mackic, 1999, Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers, Pharm. Res., 16, 1360, 10.1023/A:1018938722768 Barth, 1999, Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7), Neurosurgery, 44, 351, 10.1097/00006123-199902000-00062 Bidanset, 2001, Intravenous infusion of cereport increases uptake and efficacy of acyclovir in herpes simplex virus-infected rat brains, Antimicrob. Agents Chemother., 45, 2316, 10.1128/AAC.45.8.2316-2323.2001 Bartus, 2000, Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival, J. Pharmacol. Exp. Ther., 293, 903 Zhang, 2004, The effect of RMP-7 and its derivative on transporting Evans blue liposomes into the brain, Drug Deliv., 11, 301, 10.1080/10717540490494078 Gregor, 1999, Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group, J. Neurooncol, 44, 137, 10.1023/A:1006379332212 Warren, 2006, Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group, Cancer Chemother. Pharmacol., 58, 343, 10.1007/s00280-005-0172-7 Kuang, 2009, Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection, Virus Res., 144, 18, 10.1016/j.virusres.2009.03.014 Dallasta, 1999, Blood–brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis, Am. J. Pathol., 155, 1915, 10.1016/S0002-9440(10)65511-3 Nakamuta, 2008, Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells, J. Neurovirol., 14, 186, 10.1080/13550280801993630 Verma, 2010, Reversal of West Nile virus-induced blood–brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor, Virology, 397, 130, 10.1016/j.virol.2009.10.036 Verma, 2009, West nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood–brain barrier, Virology, 385, 425, 10.1016/j.virol.2008.11.047 Foust, 2009, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat. Biotechnol., 27, 59, 10.1038/nbt.1515 Kaplitt, 2007, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369, 2097, 10.1016/S0140-6736(07)60982-9 Doolittle, 2000, Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors, Cancer, 88, 637, 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y Sztriha, 1991, Oleic acid reversibly opens the blood–brain barrier, Brain Res., 550, 257, 10.1016/0006-8993(91)91326-V Schulze, 1997, Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells, J. Neurochem., 68, 991, 10.1046/j.1471-4159.1997.68030991.x Gan, 2008, Effect of lysophosphatidic acid increase the permeability of blood–brain barrier model, Zhonghua Yi Xue Za Zhi, 88, 416 Saija, 1997, Changes in the permeability of the blood–brain barrier following sodium dodecyl sulphate administration in the rat, Exp. Brain Res., 115, 546, 10.1007/PL00005725 Kato, 1987, Chemical composition and immunobiological activities of sodium dodecyl sulphate extracts from the cell envelopes of Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Fusobacterium nucleatum, J. Gen. Microbiol., 133, 1033 Szejtli, 1998, Introduction and general overview of cyclodextrin chemistry, Chem. Rev., 98, 1743, 10.1021/cr970022c Monnaert, 2004, Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood–brain barrier, J. Pharmacol. Exp. Ther., 310, 745, 10.1124/jpet.104.067512 Monnaert, 2004, Effects of gamma- and hydroxypropyl-gamma-cyclodextrins on the transport of doxorubicin across an in vitro model of blood–brain barrier, J. Pharmacol. Exp. Ther., 311, 1115, 10.1124/jpet.104.071845 Tilloy, 2006, Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood–brain barrier, Bioorg. Med. Chem. Lett., 16, 2154, 10.1016/j.bmcl.2006.01.049 Binkowski-Machut, 2006, How cyclodextrins can mask their toxic effect on the blood–brain barrier, Bioorg. Med. Chem. Lett., 16, 1784, 10.1016/j.bmcl.2006.01.031 Vykhodtseva, 2008, Progress and problems in the application of focused ultrasound for blood–brain barrier disruption, Ultrasonics, 48, 279, 10.1016/j.ultras.2008.04.004 Hynynen, 2001, Noninvasive MR imaging-guided focal opening of the blood–brain barrier in rabbits, Radiology, 220, 640, 10.1148/radiol.2202001804 Sheikov, 2004, Cellular mechanisms of the blood–brain barrier opening induced by ultrasound in presence of microbubbles, Ultrasound Med. Biol., 30, 979, 10.1016/j.ultrasmedbio.2004.04.010 Hynynen, 2003, The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison), Ultrasound Med. Biol., 29, 473, 10.1016/S0301-5629(02)00741-X Wijsman, 1993, Heat stress affects blood–brain barrier permeability to horseradish peroxidase in mice, Acta Neuropathol., 86, 49, 10.1007/BF00454898 Kinoshita, 2006, Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption, Proc. Natl. Acad. Sci. U.S.A., 103, 11719, 10.1073/pnas.0604318103 Treat, 2007, Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound, Int. J. Cancer, 121, 901, 10.1002/ijc.22732 Jordao, 2010, Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease, PLoS One, 5, e10549, 10.1371/journal.pone.0010549 Moriyama, 1991, Blood–brain barrier alteration after microwave-induced hyperthermia is purely a thermal effect: I, temperature and power measurements, Surg. Neurol., 35, 177, 10.1016/0090-3019(91)90068-K Albert, 1981, Reversible microwave effects on the blood–brain barrier, Brain Res., 230, 153, 10.1016/0006-8993(81)90398-X Quock, 1987, Microwave facilitation of domperidone antagonism of apomorphine-induced stereotypic climbing in mice, Bioelectromagnetics, 8, 45, 10.1002/bem.2250080107 Kiyatkin, 2009, Permeability of the blood–brain barrier depends on brain temperature, Neuroscience, 161, 926, 10.1016/j.neuroscience.2009.04.004 Lin, 1982, Microwave hyperthermia-induced blood–brain barrier alterations, Radiat. Res., 89, 77, 10.2307/3575686 Ohmoto, 1996, Sequential changes in cerebral blood flow, early neuropathological consequences and blood–brain barrier disruption following radiofrequency-induced localized hyperthermia in the rat, Int. J. Hyperthermia, 12, 321, 10.3109/02656739609022521 Williams, 1984, Effect of 2450 MHz microwave energy on the blood–brain barrier to hydrophilic molecules. D. Brain temperature and blood–brain barrier permeability to hydrophilic tracers, Brain Res., 319, 191, 10.1016/0165-0173(84)90024-9 Lange, 1991, Japanese encephalitis virus (JEV): potentiation of lethality in mice by microwave radiation, Bioelectromagnetics, 12, 335, 10.1002/bem.2250120603 Prato, 1990, Magnetic resonance imaging increases the blood–brain barrier permeability to 153-gadolinium diethylenetriaminepentaacetic acid in rats, Brain Res., 523, 301, 10.1016/0006-8993(90)91502-8 Shivers, 1987, Magnetic resonance imaging temporarily alters blood–brain barrier permeability in the rat, Neurosci. Lett., 76, 25, 10.1016/0304-3940(87)90186-8 Preston, 1989, Does magnetic resonance imaging compromise integrity of the blood–brain barrier?, Neurosci. Lett., 101, 46, 10.1016/0304-3940(89)90438-2 Liburdy, 1992, Permeability of the blood–brain barrier of the rat is not significantly altered by NMR exposure, Ann. N. Y. Acad. Sci., 649, 345, 10.1111/j.1749-6632.1992.tb49626.x Qiu, 2010, The role of protein kinase C in the opening of blood–brain barrier induced by electromagnetic pulse, Toxicology, 273, 29, 10.1016/j.tox.2010.04.013 Kuo, 2008, Electromagnetic interference in the permeability of saquinavir across the blood–brain barrier using nanoparticulate carriers, Int. J. Pharm., 351, 271, 10.1016/j.ijpharm.2007.09.020 Koo, 2006, Brain cancer diagnosis and therapy with nanoplatforms, Adv. Drug Deliv. Rev., 58, 1556, 10.1016/j.addr.2006.09.012 Bhaskar, 2010, Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging, Part. Fibre Toxicol., 7, 3, 10.1186/1743-8977-7-3 Garcia-Garcia, 2005, Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain?, Int. J. Pharm., 298, 274, 10.1016/j.ijpharm.2005.03.031 ClinicalTrials.gov, Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00944801, Last access 21st July 2011. H. Chen, Y. Qin, Q. Zhang, W. Jiang, L. Tang, J. Liu, Q. He, Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur. J. Pharm. Sci. 44 (2011) 164–173. Kateb, 2011, Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?, Neuroimage, 54, S106, 10.1016/j.neuroimage.2010.01.105 Dufes, 2000, Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting, Pharm. Res., 17, 1250, 10.1023/A:1026422915326 Arunothayanun, 2000, The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether, Int. J. Pharm., 201, 7, 10.1016/S0378-5173(00)00362-8 Discher, 2006, Polymersomes, Annu. Rev. Biomed. Eng., 8, 323, 10.1146/annurev.bioeng.8.061505.095838 Liu, 2004, Cholesteryl-grafted functional amphiphilic poly(N-isopropylacrylamide-co-N-hydroxylmethylacrylamide): synthesis, temperature-sensitivity, self-assembly and encapsulation of a hydrophobic agent, Biomaterials, 25, 2619, 10.1016/j.biomaterials.2003.09.028 Woodle, 1995, Sterically stabilized liposome therapeutics, Adv. Drug Deliv. Rev., 16, 249, 10.1016/0169-409X(95)00028-6 Hatakeyama, 2007, Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes, Int. J. Pharm., 342, 194, 10.1016/j.ijpharm.2007.04.037 Li, 2009, Targeted delivery of doxorubicin using stealth liposomes modified with transferrin, Int. J. Pharm., 373, 116, 10.1016/j.ijpharm.2009.01.023 Markoutsa, 2011, Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line, Eur. J. Pharm. Biopharm., 77, 265, 10.1016/j.ejpb.2010.11.015 Stolnik, 1995, Long circulating microparticulate drug carriers, Adv. Drug Deliv. Rev., 16, 195, 10.1016/0169-409X(95)00025-3 Coombes, 1994, Resorbable polymeric microspheres for drug delivery – production and simultaneous surface modification using PEO-PPO surfactants, Biomaterials, 15, 673, 10.1016/0142-9612(94)90165-1 Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science (Wash DC), 263, 1600, 10.1126/science.8128245 Bazile, 1995, Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system, J. Pharm. Sci., 84, 493, 10.1002/jps.2600840420 Peracchia, 1997, PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: investigation of their drug encapsulation and release characteristics, J. Control. Release, 46, 223, 10.1016/S0168-3659(96)01597-0 Calvo, 2001, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery, Pharm. Res., 18, 1157, 10.1023/A:1010931127745 Brigger, 2002, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev., 54, 631, 10.1016/S0169-409X(02)00044-3 Tsuji, 1999, Carrier-mediated or specialized transport of drugs across the blood–brain barrier, Adv. Drug Deliv. Rev., 36, 277, 10.1016/S0169-409X(98)00084-2 Wade, 1975, 3-O-methyldopa uptake and inhibition of L-dopa at the blood–brain barrier, Life Sci., 17, 131, 10.1016/0024-3205(75)90248-9 Rousselle, 2000, New advances in the transport of doxorubicin through the blood–brain barrier by a peptide vector-mediated strategy, Mol. Pharmacol., 57, 679, 10.1124/mol.57.4.679 Adenot, 2007, Applications of a blood–brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery, Chemotherapy, 53, 73, 10.1159/000098422 Zorko, 2005, Cell-penetrating peptides: mechanism and kinetics of cargo delivery, Adv. Drug Deliv. Rev., 57, 529, 10.1016/j.addr.2004.10.010 Deshayes, 2005, Cell-penetrating peptides: tools for intracellular delivery of therapeutics, Cell. Mol. Life Sci., 62, 1839, 10.1007/s00018-005-5109-0 Drin, 2003, Studies on the internalization mechanism of cationic cell-penetrating peptides, J. Biol. Chem., 278, 31192, 10.1074/jbc.M303938200 Wadia, 2004, Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis, Nat. Med., 10, 310, 10.1038/nm996 Rousselle, 2003, Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy, J. Pharmacol. Exp. Ther., 306, 371, 10.1124/jpet.102.048520 Brigati, 2003, HIV Tat, its TARgets and the control of viral gene expression, FEMS Microbiol. Lett., 220, 57, 10.1016/S0378-1097(03)00067-3 Schwarze, 1999, In vivo protein transduction: delivery of a biologically active protein into the mouse, Science, 285, 1569, 10.1126/science.285.5433.1569 Cao, 2002, In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis, J. Neurosci., 22, 5423, 10.1523/JNEUROSCI.22-13-05423.2002 Kilic, 2002, Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice, Ann. Neurol., 52, 617, 10.1002/ana.10356 Zhao, 2002, Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake, Bioconjug. Chem., 13, 840, 10.1021/bc0255236 Fretz, 2005, Strategies for cytosolic delivery of liposomal macromolecules, Int. J. Pharm., 298, 305, 10.1016/j.ijpharm.2005.02.040 Santra, 2005, Synthesis of water-dispersible fluorescent, radio-opaque, and paramagnetic CdS:Mn/ZnS quantum dots: a multifunctional probe for bioimaging, J. Am. Chem. Soc., 127, 1656, 10.1021/ja0464140 Liu, 2008, Polymeric micelles anchored with TAT for delivery of antibiotics across the blood–brain barrier, Biopolymers, 90, 617, 10.1002/bip.20998 Wang, 2010, The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis, Biomaterials, 31, 2874, 10.1016/j.biomaterials.2009.12.042 Y. Qin, H. Chen, W. Yuan, R. Kuai, Q. Zhang, F. Xie, L. Zhang, Z. Zhang, J. Liu, Q. He, Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 420 (2011) 304–312. Poduslo, 1996, Polyamine modification increases the permeability of proteins at the blood–nerve and blood–brain barriers, J. Neurochem., 66, 1599, 10.1046/j.1471-4159.1996.66041599.x Lu, 2007, Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle, J. Control. Release, 118, 38, 10.1016/j.jconrel.2006.11.015 Saar, 2005, Cell-penetrating peptides: a comparative membrane toxicity study, Anal. Biochem., 345, 55, 10.1016/j.ab.2005.07.033 Cardozo, 2007, Cell-permeable peptides induce dose- and length-dependent cytotoxic effects, Biochim. Biophys. Acta(BBA) - Biomembranes, 1768, 2222, 10.1016/j.bbamem.2007.06.003 Kilic, 2002, Intravenous Tat-Bcl-XL is protective after middle cerebral artery occlusion in mice, Ann. Neurol., 52, 617, 10.1002/ana.10356 Fawell, 1994, Tat-mediated delivery of heterologous proteins into cells, Proc. Natl. Acad. Sci. U.S.A., 91, 664, 10.1073/pnas.91.2.664 Nagahara, 1998, Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration, Nat. Med., 4, 1449, 10.1038/4042 Sabatier, 1991, Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1, J. Virol., 65, 961, 10.1128/JVI.65.2.961-967.1991 Pardridge, 2002, Drug and gene targeting to the brain with molecular Trojan horses, Nat. Rev. Drug Discov., 1, 131, 10.1038/nrd725 Pardridge, 1995, Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood–brain barrier in vivo, Proc. Natl. Acad. Sci. U.S.A., 92, 5592, 10.1073/pnas.92.12.5592 Zhang, 2001, Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin, Brain Res., 889, 49, 10.1016/S0006-8993(00)03108-5 Bartsch, 2005, Cell-specific targeting of lipid-based carriers for ODN and DNA, J. Liposome Res., 15, 59, 10.1081/LPR-200064961 Shir, 2006, EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice, PLoS Med., 3, e6, 10.1371/journal.pmed.0030006 Raab, 1997, Heparin-binding EGF-like growth factor, Biochim. Biophys. Acta, 1333, F179 Gabathuler, 2010, Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases, Neurobiol. Dis., 37, 48, 10.1016/j.nbd.2009.07.028 Pardridge, 1985, Human blood–brain barrier insulin receptor, J. Neurochem., 44, 1771, 10.1111/j.1471-4159.1985.tb07167.x Pardridge, 1995, Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate, Pharm. Res., 12, 807, 10.1023/A:1016244500596 Zhang, 2003, Marked enhancement in gene expression by targeting the human insulin receptor, J. Gene Med., 5, 157, 10.1002/jgm.333 Xia, 2009, Antibody-mediated targeting of siRNA via the human insulin receptor using avidin–biotin technology, Mol. Pharm., 6, 747, 10.1021/mp800194y Wu, 1997, Drug targeting of a peptide radiopharmaceutical through the primate blood–brain barrier in vivo with a monoclonal antibody to the human insulin receptor, J. Clin. Invest., 100, 1804, 10.1172/JCI119708 Boado, 2007, Humanization of anti-human insulin receptor antibody for drug targeting across the human blood–brain barrier, Biotechnol. Bioeng., 96, 381, 10.1002/bit.21120 Moos, 2000, Transferrin and transferrin receptor function in brain barrier systems, Cell. Mol. Neurobiol., 20, 77, 10.1023/A:1006948027674 da Cruz, 2004, Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons, Exp. Neurol., 187, 65, 10.1016/j.expneurol.2003.12.013 Lee, 2000, Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood–brain barrier in mouse, J. Pharmacol. Exp. Ther., 292, 1048 Ulbrich, 2009, Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB), Eur. J. Pharm. Biopharm., 71, 251, 10.1016/j.ejpb.2008.08.021 van Rooy, 2011, Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain, J. Control. Release, 150, 30, 10.1016/j.jconrel.2010.11.014 Schröder, 1996, Nanoparticles, a drug carrier system to pass the blood–brain barrier, permit central analgesic effects of i.v. dalargin injections, Brain Res., 710, 121, 10.1016/0006-8993(95)01375-X Blasi, 2007, Solid lipid nanoparticles for targeted brain drug delivery, Adv. Drug Deliv. Rev., 59, 454, 10.1016/j.addr.2007.04.011 Zensi, 2009, Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones, J. Control. Release, 137, 78, 10.1016/j.jconrel.2009.03.002 Yuan, 2006, New insights into eNOS signaling in microvascular permeability, Am. J. Physiol. Heart Circ. Physiol., 291, H1029, 10.1152/ajpheart.00509.2006 Leveugle, 1994, The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis, Brain Res., 650, 20, 10.1016/0006-8993(94)90202-X Fillebeen, 1999, Receptor-mediated transcytosis of lactoferrin through the blood–brain barrier, J. Biol. Chem., 274, 7011, 10.1074/jbc.274.11.7011 Huang, 2007, Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain, J. Biomed. Sci., 14, 121, 10.1007/s11373-006-9121-7 Ji, 2006, Pharmacokinetics and brain uptake of lactoferrin in rats, Life Sci., 78, 851, 10.1016/j.lfs.2005.05.085 Hu, 2009, Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations, J. Control. Release, 134, 55, 10.1016/j.jconrel.2008.10.016 Hu, 2011, Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease, Int. J. Pharm., 415, 273, 10.1016/j.ijpharm.2011.05.062 Hu, 2011, Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease, Int. J. Pharm., 415, 273, 10.1016/j.ijpharm.2011.05.062 Demeule, 2002, High transcytosis of melanotransferrin (P97) across the blood–brain barrier, J. Neurochem., 83, 924, 10.1046/j.1471-4159.2002.01201.x Gabathuler, 2005, Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood–brain barrier, Int. Congr. Ser., 1277, 171, 10.1016/j.ics.2005.02.021 Raptor, Raptor Pharmaceutical Corp entered a research collaboration and license agreement with Roche in June 2009, http://www.raptorpharma.com/science_neurotrans.html, Last access 27th July, 2011. Demeule, 2008, Identification and design of peptides as a new drug delivery system for the brain, J. Pharmacol. Exp. Ther., 324, 1064, 10.1124/jpet.107.131318 Demeule, 2008, Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2, J. Neurochem., 106, 1534, 10.1111/j.1471-4159.2008.05492.x Ke, 2009, Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer, Biomaterials, 30, 6976, 10.1016/j.biomaterials.2009.08.049 Shao, 2010, Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain, J. Control. Release, 147, 118, 10.1016/j.jconrel.2010.06.018 Thomas, 2009, Uptake of ANG1005, a novel paclitaxel derivative, through the blood–brain barrier into brain and experimental brain metastases of breast cancer, Pharm. Res., 26, 2486, 10.1007/s11095-009-9964-5 Regina, 2008, Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2, Br. J. Pharmacol., 155, 185, 10.1038/bjp.2008.260 Tosi, 2010, Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution, J. Control. Release, 145, 49, 10.1016/j.jconrel.2010.03.008 Giannini, 1984, The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197, Nucleic Acids Res., 12, 4063, 10.1093/nar/12.10.4063 Kaefer, 2000, A nontoxic diphtheria toxin analogue inhibits neonatal bladder smooth muscle cell proliferation, J. Urol., 163, 580, 10.1016/S0022-5347(05)67936-0 Anderson, 1983, Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197, Infect. Immun., 39, 233, 10.1128/IAI.39.1.233-238.1983 Buzzi, 2004, CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients, Cancer Immunol. Immunother., 53, 1041, 10.1007/s00262-004-0546-4 Gaillard, 2006, A novel opportunity for targeted drug delivery to the brain, J. Control. Release, 116, e60, 10.1016/j.jconrel.2006.09.050 Fromm, 2000, P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs, Int. J. Clin. Pharmacol. Ther., 38, 69, 10.5414/CPP38069 Miller, 1997, Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption, Bioconjug. Chem., 8, 649, 10.1021/bc970118d Kabanov, 2003, Pluronic block copolymers as modulators of drug efflux transporter activity in the blood–brain barrier, Adv. Drug Deliv. Rev., 55, 151, 10.1016/S0169-409X(02)00176-X Batrakova, 1999, Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers, Pharm. Res., 16, 1366, 10.1023/A:1018990706838 Batrakova, 2003, Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells, J. Pharmacol. Exp. Ther., 304, 845, 10.1124/jpet.102.043307 Batrakova, 2001, Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies, J. Pharmacol. Exp. Ther., 296, 551 Batrakova, 2004, Effect of pluronic P85 on ATPase activity of drug efflux transporters, Pharm. Res., 21, 2226, 10.1007/s11095-004-7675-5 Batrakova, 1998, Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells, Pharm. Res., 15, 1525, 10.1023/A:1011942814300 Sharma, 2008, Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant, J. Control. Release, 131, 220, 10.1016/j.jconrel.2008.07.031 Rogers, 2005, Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging, Atherosclerosis, 178, 67, 10.1016/j.atherosclerosis.2004.08.017 Panyam, 2003, Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells, Pharm. Res., 20, 212, 10.1023/A:1022219003551 Daleke, 1990, Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay, Biochim. Biophys. Acta, 1024, 352, 10.1016/0005-2736(90)90365-U Rodrigueza, 1993, The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo, Biochim. Biophys. Acta, 1153, 9, 10.1016/0005-2736(93)90270-A Qin, 2007, Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain, Chem. Pharm. Bull.(Tokyo), 55, 1192, 10.1248/cpb.55.1192 Mehta, 1982, Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes, J. Reticuloendothel. Soc., 32, 155 Bender, 1996, Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro, Antimicrob. Agents Chemother., 40, 1467, 10.1128/AAC.40.6.1467 Koff, 1985, Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon, Cancer Immunol. Immunother., 19, 85, 10.1007/BF00199714 Koff, 1984, Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells, Science, 224, 1007, 10.1126/science.6426057 von zur Muhlen, 2010, Imaging monocytes with iron oxide nanoparticles targeted towards the monocyte integrin MAC-1 (CD11b/CD18) does not result in improved atherosclerotic plaque detection by in vivo MRI, Contrast Media Mol. Imaging, 5, 268, 10.1002/cmmi.384 Jones, 2007, Blood–brain barrier transport of therapeutics via receptor-mediation, Pharm. Res., 24, 1759, 10.1007/s11095-007-9379-0 Minagar, 2003, Blood–brain barrier disruption in multiple sclerosis, Mult. Scler., 9, 540, 10.1191/1352458503ms965oa Wijesuriya, 2010, ABC efflux transporters in brain vasculature of Alzheimer's subjects, Brain Res., 1358, 228, 10.1016/j.brainres.2010.08.034 Palmer, 2010, The role of the blood-CNS barrier in CNS disorders and their treatment, Neurobiol. Dis., 37, 3, 10.1016/j.nbd.2009.07.029 Toborek, 2005, Mechanisms of the blood–brain barrier disruption in HIV-1 infection, Cell. Mol. Neurobiol., 25, 181, 10.1007/s10571-004-1383-x Gottfredsson, 2000, Fungal meningitis, Semin. Neurol., 20, 307, 10.1055/s-2000-9394 Lee, 2006, Blood–brain barrier dysfunction occurring in mice infected with Angiostrongylus cantonensis, Acta Trop., 97, 204, 10.1016/j.actatropica.2005.11.003 Stolp, 2011, Effects of neonatal systemic inflammation on blood–brain barrier permeability and behaviour in juvenile and adult rats, Cardiovasc. Psychiatry Neurol., 2011, 469046, 10.1155/2011/469046 Habgood, 2007, Changes in blood–brain barrier permeability to large and small molecules following traumatic brain injury in mice, Eur. J. Neurosci., 25, 231, 10.1111/j.1460-9568.2006.05275.x Brooks, 2006, Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain, Brain Res., 1120, 172, 10.1016/j.brainres.2006.08.085 Maeda, 2009, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010 Soni, 2008, Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain, J. Drug Target., 16, 73, 10.1080/10611860701725381 Doi, 2008, Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy, J. Neurooncol, 87, 287, 10.1007/s11060-008-9522-8 Tanaka, 1999, Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury, Brain Res., 827, 130, 10.1016/S0006-8993(99)01319-0 Simon, 2011, TAT is not capable of transcellular delivery across an intact endothelial monolayer in vitro, Ann. Biomed. Eng., 39, 394, 10.1007/s10439-010-0144-x Kumar, 2007, Transvascular delivery of small interfering RNA to the central nervous system, Nature, 448, 39, 10.1038/nature05901 Gandhi, 2010, Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood–brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder, J. Neurovirol., 16, 294, 10.3109/13550284.2010.499891 Kaur, 2008, Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation, Acta Pharm., 58, 61, 10.2478/v10007-007-0045-1 Dou, 2009, Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS, J. Immunol., 183, 661, 10.4049/jimmunol.0900274 Williams, 1984, Effect of 2450 MHz microwave energy on the blood–brain barrier to hydrophilic molecules, A. Effect on the permeability to sodium fluorescein, Brain Res., 319, 165, 10.1016/0165-0173(84)90021-3 Yang, 2007, Quantitative evaluation of focused ultrasound with a contrast agent on blood–brain barrier disruption, Ultrasound Med. Biol., 33, 1421, 10.1016/j.ultrasmedbio.2007.04.006 Liu, 2010, Opening of the blood–brain barrier by low-frequency (28-kHz) ultrasound: a novel pinhole-assisted mechanical scanning device, Ultrasound Med. Biol., 36, 325, 10.1016/j.ultrasmedbio.2009.10.004 Lindgren, 2000, Cell-penetrating peptides, Trends Pharmacol. Sci., 21, 99, 10.1016/S0165-6147(00)01447-4 Snyder, 2004, Cell penetrating peptides in drug delivery, Pharm. Res., 21, 389, 10.1023/B:PHAM.0000019289.61978.f5 Temsamani, 2004, The use of cell-penetrating peptides for drug delivery, Drug Discov. Today, 9, 1012, 10.1016/S1359-6446(04)03279-9